Celleron’s Chief Medical Officer David Kerr to Deliver Guest Presentation at WuXi Healthcare Forum 2021

Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by its Chief Medical Officer, Professor David Kerr, at the WuXi Healthcare Forum 2021.

The second annual WuXi Healthcare Forum will launch virtually from 15-18 March 2021. This event, titled “Partnership for Patients,” brings together over 6,000 colleagues from around the world who are working to address global healthcare challenges with global solutions. It will explore critical issues that impact our ability to advance medicines faster for patients, and to shape the future of healthcare.

The Forum will bring together over 70 industry thought leaders who are working collaboratively to address global healthcare challenges with global solutions.

Plenary sessions and satellite forums will focus on the partnership and innovation across the R&D value chain, crossing borders and industries, to deliver medical advancements that will benefit people globally.

CEO Roundtable sessions will be hosted for innovative companies who are looking to showcase their leading technologies, products and R&D efforts to a global audience of potential partners, entrepreneurs, executives and investors. The Forum anticipates involvement from 200+ innovative companies across drug R&D, medtech, and health tech. Each company will host up to two virtual sessions of presentation/Q&A tailored to accommodate different time zones for business networking and partnering with executives in R&D and investment community.

Professor David Kerr, CMO, commented: ”This is one of the most important life science events of the year and plays to Celleron’s strengths in precision cancer medicine and elements of its drug portfolio, which are of particular relevance for Asian patients.”

For more details, please visit www.wuxionline.com/WHF2021

About Celleron Therapeutics

Celleron Therapeutics is a clinical stage biopharmaceutical company developing a portfolio of best-in-class therapies to treat cancer indications with unmet medical need. The company is a spin-out from Oxford University and is located at the Oxford Science Park, UK.

Celleron has exclusive worldwide rights to zabinostat (CXD101) through a global licensing partnership with AstraZeneca. The company secured investment in 2016 from a consortium of South Korean investors. In 2020, Celleron incorporated SynOx Therapeutics, a portfolio company dedicated to the development of emactuzumab, and secured EUR 37M to support the company from a syndicate of blue-chip VC investors.

Celleron is managed by a highly experienced team with proven track records, and its strong relationship with Oxford University provides access to an extensive global clinical and scientific network. For more information, please visit www.cellerontherapeutics.com

Download the Press release here: